1. New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine H 3 Receptor (H3R) Antagonism and Calcium Channels Blockade with Additional Cholinesterase Inhibition.
- Author
-
Malek R, Arribas RL, Palomino-Antolin A, Totoson P, Demougeot C, Kobrlova T, Soukup O, Iriepa I, Moraleda I, Diez-Iriepa D, Godyń J, Panek D, Malawska B, Głuch-Lutwin M, Mordyl B, Siwek A, Chabchoub F, Marco-Contelles J, Kiec-Kononowicz K, Egea J, de Los Ríos C, and Ismaili L
- Subjects
- Alzheimer Disease metabolism, Animals, Calcium Channel Blockers chemistry, Cholinesterase Inhibitors chemistry, Humans, Memory Disorders drug therapy, Memory Disorders metabolism, Mice, Neuroblastoma drug therapy, Neuroblastoma metabolism, Neuroprotective Agents chemistry, Small Molecule Libraries chemistry, Tumor Cells, Cultured, Vasodilator Agents chemistry, Alzheimer Disease drug therapy, Calcium Channel Blockers pharmacology, Cholinesterase Inhibitors pharmacology, Neuroprotective Agents pharmacology, Receptors, Histamine H3 chemistry, Small Molecule Libraries pharmacology, Vasodilator Agents pharmacology
- Abstract
New tritarget small molecules combining Ca
2+ channels blockade, cholinesterase, and H3 receptor inhibition were obtained by multicomponent synthesis. Compound 3p has been identified as a very promising lead, showing good Ca2+ channels blockade activity (IC50 = 21 ± 1 μM), potent affinity against hH3R ( Ki = 565 ± 62 nM), a moderate but selective hBuChE inhibition (IC50 = 7.83 ± 0.10 μM), strong antioxidant power (3.6 TE), and ability to restore cognitive impairment induced by lipopolysaccharide.- Published
- 2019
- Full Text
- View/download PDF